New approaches to anticancer drug design

S.A. Kondratyeva

New approaches to anticancer drug design

S.A. Kondratyeva¹

research article Pages: 27-29

¹ студент 5-го курса, кафедра биоорганической химии, биологический факультет, Московский государственный университет им. М.В. Ломоносова

Keywords: antitumor drugs gene therapy

Abstract

Main research directions of anticancer drugs investigations are considered, including the increase of the drugs specificity and solving the problem of their targeted delivery.

How to cite

Кондратьева С.А. Новые подходы к созданию противоопухолевых препаратов направленного действия // Вопросы биологической, медицинской и фармацевтической химии. 2013. № 6. С. 27–29.

References

ChenJ. etal.A restricted cell population propagates glioblastoma growth after chemotherapy // Nature. 2012. V. 488. № 7412. P. 522-526.
Driessens G. et al. Defining the mode of tumour growth by clonal analysis // Nature. 2012.
Schepers A.G. et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas // Science Signaling. 2012. V. 337. № 6095. P. 730.
Thiery J.P. et al. Epithelial-mesenchymal transitions in development and disease // Cell. 2009. V. 139. № 5. P. 871-890.
Clayton S., Mousa S.A. Therapeutics formulated to target cancer stem cells: Is it in our future - // Cancer cell international. 2011. V. 11. № 1. P. 7.
Grotenhuis B.A. et al. Preoperative Assessment of Tumor Location and Station-Specific Lymph Node Status in Patients with Adenocarcinoma of the Gastroesophageal Junction // World journal of surgery. 2013. V. 37. № 1. P. 147-155.
Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities // Cell Stem Cell. 2012. V. 10. № 6. P. 717-728.
Severin E., Rodina A. Problemy' i perspektivy' sovremennoj protivoopuxolevoj terapii // Uspexi biologicheskoj ximii. 2006. № 46. P. 43-64.
Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential // International journal of nanomedicine. 2006. V. 1. № 3. P. 297.
Storm G., Crommelin D.J. Liposomes: quo vadis - // Pharmaceutical Science & Technology Today. 1998. V. 1. № 1. P. 19-31.
Stefani A.-L. et al. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma // Journal of hepatology. 2005. V. 42. № 5. P. 728-735.
Leal J.A., Feliciano A. and LLeonart M.E. Stem cell MicroRNAs in senescence and immortalization: novel players in cancer therapy // Medicinal Research Reviews. 2013. V. 33. № 1. P. 112-138.
Davis T.A. et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin-s lymphoma: safety and efficacy of re-treatment // Journal of Clinical Oncology. 2000. V. 18. № 17. P. 3135-3143.
Martinelli E. et al. Anti‐epidermal growth factor receptor monoclonal antibodies in cancer therapy // Clinical & Experimental Immunology. 2009. V. 158. № 1. P. 1-9.
Witzig T.E. et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin-s lymphoma // Journal of Clinical Oncology. 2002. V. 20. № 10. P. 2453-2463.
Semenza G.L. Hypoxia-inducible factors in physiology and medicine // Cell. 2012. V. 148. № 3. P. 399-408.
Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation // Cell. 2011. V. 144. № 5. P. 646-674.

[1] ChenJ. etal.A restricted cell population propagates glioblastoma growth after chemotherapy // Nature. 2012. V. 488. № 7412. P. 522-526.

[2] Driessens G. et al. Defining the mode of tumour growth by clonal analysis // Nature. 2012.

[3] Schepers A.G. et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas // Science Signaling. 2012. V. 337. № 6095. P. 730.

[4] Thiery J.P. et al. Epithelial-mesenchymal transitions in development and disease // Cell. 2009. V. 139. № 5. P. 871-890.

[5] Clayton S., Mousa S.A. Therapeutics formulated to target cancer stem cells: Is it in our future - // Cancer cell international. 2011. V. 11. № 1. P. 7.

[6] Grotenhuis B.A. et al. Preoperative Assessment of Tumor Location and Station-Specific Lymph Node Status in Patients with Adenocarcinoma of the Gastroesophageal Junction // World journal of surgery. 2013. V. 37. № 1. P. 147-155.

[7] Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities // Cell Stem Cell. 2012. V. 10. № 6. P. 717-728.

[8] Severin E., Rodina A. Problemy' i perspektivy' sovremennoj protivoopuxolevoj terapii // Uspexi biologicheskoj ximii. 2006. № 46. P. 43-64.

[9] Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential // International journal of nanomedicine. 2006. V. 1. № 3. P. 297.

[10] Storm G., Crommelin D.J. Liposomes: quo vadis - // Pharmaceutical Science & Technology Today. 1998. V. 1. № 1. P. 19-31.

[11] Stefani A.-L. et al. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma // Journal of hepatology. 2005. V. 42. № 5. P. 728-735.

[12] Leal J.A., Feliciano A. and LLeonart M.E. Stem cell MicroRNAs in senescence and immortalization: novel players in cancer therapy // Medicinal Research Reviews. 2013. V. 33. № 1. P. 112-138.

[13] Davis T.A. et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin-s lymphoma: safety and efficacy of re-treatment // Journal of Clinical Oncology. 2000. V. 18. № 17. P. 3135-3143.

[14] Martinelli E. et al. Anti‐epidermal growth factor receptor monoclonal antibodies in cancer therapy // Clinical & Experimental Immunology. 2009. V. 158. № 1. P. 1-9.

[15] Witzig T.E. et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin-s lymphoma // Journal of Clinical Oncology. 2002. V. 20. № 10. P. 2453-2463.

[16] Semenza G.L. Hypoxia-inducible factors in physiology and medicine // Cell. 2012. V. 148. № 3. P. 399-408.

[17] Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation // Cell. 2011. V. 144. № 5. P. 646-674.